Sector: Health Technology
Description: Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
Shares Outstanding: 46514400
Next Earning Date:2020-11-10
TTm EPS: -4.4181
TTm Dividend Rate:
200 days moving average:17.12
50 days moving average: 13.63
One day percent Change: -1.93
Any information, commentary, recommendations or statements of opinion provided here are for general information purposes only.
It is not intended to be personalised investment advice or a solicitation for the purchase or sale of securities.
Before purchasing any discussed securities, please be sure actions are in line with your investment objectives,
financial situation and particular needs. International investors may be subject to additional risks arising from currency
fluctuations and/or local taxes or restrictions. The information contained in this publication are obtained from, or
based upon publicly available sources that we believe to reliable, but we make no warranty as to their accuracy or usefulness
of the information provided, and accepts no liability for losses incurred by readers using research.
Recommendations and opinions are subject to change without notice. Please remember that investments can go up and down,
including the possibility a stock could lose all of its value. Past performance is not indicative of future results.
Copyright © www.ndimensionshares.com